文献速递肝病

非诺贝特作为原发性胆汁性胆管炎二线治疗的长期回顾性研究

Long-Term Use of Fenofibrate as Second-Line Therapy in Primary Biliary Cholangitis: A Retrospective Study.
PubMed 文献 · Aliment Pharmacol Ther · 2026-02-18

本研究为单中心回顾性队列,纳入59例UDCA应答不佳的原发性胆汁性胆管炎患者,接受非诺贝特平均44.8个月。ALP正常化中位时间9.5个月,未达Paris II标准者11.2个月;GLOBE评分显著改善,UK-PBC与FIB-4稳定,仅5%因肝酶升高停药。

要点

  • 非诺贝特长期治疗可改善UDCA应答不佳PBC患者的胆汁淤积指标。
  • ALP正常化中位时间9.5个月,未达Paris II标准者为11.2个月。
  • GLOBE评分显著改善,UK-PBC评分与FIB-4保持稳定。

核心结论

  • 在UDCA应答不足的PBC患者长期队列中,非诺贝特随时间显著改善胆汁淤积标志物和预后评分。
  • 鉴于其良好安全性,非诺贝特应进一步考虑作为可及且经济的PBC二线治疗。

研究设计与样本

  • 单中心回顾性队列研究,纳入2012至2024年间因UDCA治疗后ALP持续升高而处方非诺贝特的PBC患者。
  • 共纳入59例患者,非诺贝特平均治疗时长44.8个月。

主要发现

  • 总体ALP正常化中位时间为9.5个月。
  • 非诺贝特治疗前未满足Paris II标准者,ALP正常化中位时间为11.2个月。
  • GLOBE预后评分随非诺贝特治疗显著改善。
  • UK-PBC评分与纤维化指数FIB-4保持稳定。
  • 大多数患者耐受良好,仅5%因肝酶升高停药。

关键数值与推荐

  • 近40%的PBC患者对一线UDCA治疗应答不完全。
  • 非诺贝特为过氧化物酶体增殖物激活受体α(PPAR-α)激动剂。

临床怎么用

  • 对UDCA应答不佳的PBC患者,可考虑非诺贝特作为二线治疗选项。
  • 治疗期间应监测ALP以评估生化应答,并关注肝酶变化。

局限性

  • 本研究为单中心回顾性队列研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Nearly 40% of patients with primary biliary cholangitis (PBC) have an incomplete response to first-line ursodeoxycholic acid (UDCA) therapy. Fenofibrate, a peroxisome proliferator-activated receptor alpha (PPAR-α) agonist, is an effective second-line treatment for PBC. Compared to the recently FDA-approved PPAR agonists, fenofibrate may provide a more cost-effective and accessible alternative. However, longitudinal data on fenofibrate use in PBC are lacking. Here, we review our experience using fenofibrate in PBC and its long-term effects on cholestatic biomarkers, prognostic scores, and fibrosis indices. APPROACH AND RESULTS: This single-centre retrospective cohort study examined PBC patients prescribed fenofibrate between 2012 and 2024 for persistent elevations in alkaline phosphatase (ALP) despite UDCA therapy. The study included 59 patients treated with fenofibrate for a mean duration of 44.8 months. The overall median time to ALP normalisation was 9.5 months. Of those who did not meet Paris II criteria prior to fenofibrate therapy, the median time to ALP normalisation was 11.2 months. GLOBE prognostic scores significantly improved with fenofibrate therapy, while UK-PBC scores and fibrosis index scores (FIB-4) remained stable. Fenofibrate was well-tolerated by most patients, with only 5% of patients discontinuing therapy due to elevated liver enzymes. CONCLUSIONS: In this long-term cohort of PBC patients with insufficient response to UDCA, fenofibrate significantly improved cholestatic markers and prognostic scores over time. Given this, and its favourable safety profile, fenofibrate should be further considered as an accessible and affordable second-line therapy in PBC.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Maxwell M, Deng Y, Chen B, et al. Long-Term Use of Fenofibrate as Second-Line Therapy in Primary Biliary Cholangitis: A Retrospective Study. Aliment Pharmacol Ther. 2026. PMID: 41705340. doi:10.1111/apt.70574

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。